

### SECTION-1: Identification of the substance / mixture and the company / undertaking

<b>Catalogue Number</b>	CS-T-85612
<b>Product Name</b>	Rimegepant
<b>CAS No.</b>	1289023-67-1
<b>Category</b>	API
<b>Synonyms</b>	Not available
<b>Brand</b>	Clearsynth Labs Ltd.
<b>Identified uses</b>	Laboratory Chemicals
<b>Uses advised against</b>	Not available
<b>Company</b>	Clearsynth Labs Ltd. Mumbai, India
<b>Emergency Phone #</b>	+91-22-245045900
<b>REACH No.</b>	Not available

### SECTION 2: Hazards identification

**Disclaimer:** This is sample MSDS. Please email [sales@clearsynth.com](mailto:sales@clearsynth.com) for more details.

#### 2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

#### 2.2 Label Elements

**Signal Word:** Not available

Not available

#### Hazard Statement(s)

Code	Statement
Not available	Not available

#### Precautionary Statement(s)

Code	Statement
Not available	Not available

### SECTION 3: Composition / information on ingredients

#### 3.1 Substance

Component : Rimegepant  
CAS Number : 1289023-67-1  
Molecular Formula : C<sub>28</sub>H<sub>28</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub>  
Molecular Weight : 534.6  
Parent Chemical : Rimegepant  
Synonyms : Not available  
Concentration : Not available

### SECTION 4: First aid measures

#### SECTION 4: First-aid measures

##### 4.1 Description of first aid measures

Inhalation: Remove person to fresh air. If symptoms occur or persist, get medical attention.

Skin contact: Wash with plenty of soap and water. Remove contaminated clothing and wash before reuse. Get medical attention if irritation develops or persists.

Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Get medical attention if irritation persists.

Ingestion: Rinse mouth. Do NOT induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person. Get medical attention.

##### 4.2 Most important symptoms/effects, acute and delayed

Not available.

##### 4.3 Indication of immediate medical attention and special treatment needed

Treat symptomatically. No data available.

### SECTION 5: Firefighting measures

#### SECTION 5: Fire-fighting measures

##### 5.1 Suitable extinguishing media

Use extinguishing media appropriate for surrounding fire (e.g., water spray, alcohol-resistant foam, dry chemical, carbon dioxide).

##### 5.2 Special hazards arising from the substance or mixture

No data available. Combustion may produce carbon oxides, nitrogen oxides, and other irritating/toxic fumes.

##### 5.3 Advice for firefighters

Wear self-contained breathing apparatus (SCBA) and full protective gear. Cool containers with water spray if exposed to fire. Avoid inhalation of combustion products.

### SECTION 6: Accidental release measures

#### SECTION 6: Accidental release measures

##### 6.1 Personal precautions, protective equipment and emergency procedures

Avoid breathing dust. Avoid contact with skin and eyes. Use appropriate personal protective equipment. Ensure adequate ventilation.

##### 6.2 Environmental precautions

Avoid release to the environment. Prevent entry into drains, surface water, or soil.

### 6.3 Methods and material for containment and cleaning up

Contain spill. For solids: carefully sweep or scoop up without generating dust and place in a suitable, labeled container for disposal. Clean spill area with appropriate methods. Dispose of waste in accordance with local regulations.

### 6.4 Reference to other sections

See Section 8 for personal protective equipment and Section 13 for disposal considerations.

## SECTION-7: Handling and storage

### SECTION 7: Handling and storage

#### 7.1 Precautions for safe handling

Handle in accordance with good industrial hygiene and safety practice. Avoid formation of dust and aerosols. Avoid contact with skin, eyes, and clothing. Do not breathe dust. Use with adequate ventilation.

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in a tightly closed container in a cool, dry, well-ventilated place. Protect from moisture. Keep away from incompatible materials.

Incompatible materials: Not available.

#### 7.3 Specific end use(s)

API / laboratory or industrial use. Not for food, drug, or household use. Specific uses: Not available.

## SECTION 8: Exposure controls / personal protection

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

Occupational exposure limits: Not available.

Biological limit values: Not available.

#### 8.2 Exposure controls

Engineering controls: Use local exhaust ventilation or other engineering controls to maintain airborne levels as low as practicable.

Personal protective equipment (PPE):

- Eye/face protection: Safety glasses with side shields or chemical goggles.
- Skin protection: Protective gloves. Wear appropriate protective clothing.
- Respiratory protection: If ventilation is inadequate or dust is generated, use a suitable particulate respirator in accordance with applicable standards.
- Hygiene measures: Wash hands after handling. Do not eat, drink, or smoke when using this product. Remove contaminated clothing and wash before reuse.

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

## SECTION 10: Stability and reactivity

SECTION 10: Stability and reactivity

10.1 Reactivity

No data available.

### 10.2 Chemical stability

Stable under recommended storage conditions.

### 10.3 Possibility of hazardous reactions

No data available.

### 10.4 Conditions to avoid

Avoid dust formation. Avoid heat, sparks, open flames, and other ignition sources. Avoid moisture (if applicable).

### 10.5 Incompatible materials

Not available.

### 10.6 Hazardous decomposition products

No data available. Thermal decomposition/combustion may produce carbon oxides, nitrogen oxides, and other irritating/toxic fumes.

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

- Acute toxicity: In preregistration controlled trials of rimegepant in several thousand patients, mild-to-moderate serum aminotransferase elevations arose in a small percentage of patients (1% to 2%) and overall rates were not different from those in placebo recipients. In the controlled trials and subsequently with general use, there have been no reports of clinically apparent liver injury attributed to rimegepant. In contrast, telcagepant, the initial oral CGRP receptor antagonist evaluated as therapy for migraine headaches, was abandoned during development because of several instances of clinically apparent liver injury in recipients that was characterized by marked elevations in serum aminotransferase levels and symptoms of fatigue, nausea and abdominal discomfort arising within 2 to 4 weeks of starting therapy which rapidly resolved with stopping therapy. Similar episodes have not been reported with rimegepant. Likelihood score: E (unlikely cause of clinically apparent acute liver injury).

- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: No data available.
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: No data available.
- Aspiration hazard: No data available.

#### Likely routes of exposure

- No data available.

#### Symptoms related to the physical, chemical and toxicological characteristics

- In preregistration controlled trials of rimegepant in several thousand patients, mild-to-moderate serum aminotransferase elevations arose in a small percentage of patients (1% to 2%) and overall rates were not different from those in placebo recipients. In the controlled trials and subsequently with general use, there have been no reports of clinically apparent liver injury attributed to rimegepant. In contrast, telcagepant, the initial oral CGRP receptor antagonist evaluated as therapy for migraine headaches, was abandoned during development because of several instances of clinically apparent liver injury in recipients that was characterized by marked elevations in serum aminotransferase levels and symptoms of fatigue, nausea and abdominal discomfort arising within 2 to 4 weeks of starting therapy which rapidly resolved with stopping therapy. Similar episodes have not been reported with rimegepant. Likelihood score: E (unlikely cause of clinically apparent acute liver injury).

### SECTION 12: Ecological information

#### SECTION 12: Ecological information

##### 12.1 Toxicity

Not available.

##### 12.2 Persistence and degradability

Not available.

##### 12.3 Bioaccumulative potential

Not available.

##### 12.4 Mobility in soil

Not available.

##### 12.5 Results of PBT and vPvB assessment

Not available.

##### 12.6 Endocrine disrupting properties

Not available.

##### 12.7 Other adverse effects

Not available.

### SECTION 13: Disposal considerations

#### SECTION 13: Disposal considerations

##### 13.1 Waste treatment methods

Dispose of contents/container in accordance with local/regional/national/international regulations.

Do not discharge to drains or the environment.

Recommended disposal method: Not available.

Contaminated packaging: Dispose of as unused product unless cleaned and reconditioned in accordance with regulations.

### SECTION 14: Transport information

#### SECTION 14: Transport information

##### 14.1 UN number

Not available.

##### 14.2 UN proper shipping name

Not available.

##### 14.3 Transport hazard class(es)

Not available.

##### 14.4 Packing group

Not available.

##### 14.5 Environmental hazards

Not available.

14.6 Special precautions for user

Not available.

14.7 Maritime transport in bulk according to IMO instruments

Not available.

### SECTION 15: Regulatory information

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not available.

15.2 Chemical safety assessment

Not available.

### SECTION 16: Other information

SECTION 16: Other information

Product name: Rimegepant

Catalog No.: CS-T-85612

CAS No.: 1289023-67-1

Category: API

Supplier: Clearsynth Labs Ltd., Mumbai, India

Emergency phone: +91-22-245045900

Revision date: 2026-03-20

Disclaimer: The information provided is based on data available at the time of preparation and is intended for guidance in safe handling, use, processing, storage, transportation, disposal, and release. It does not constitute a warranty of any kind. Users are responsible for compliance with applicable laws and regulations.

### DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.